CHIMERIC
THERAPEUTICS

APPENDIX 4C

Quarter Ended 30 June 2025

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

ASX ANNOUNCEMENT **29 July 2025**

QUARTERLY ACTIVITIES REPORT FOR THE PERIOD ENDING 30 JUNE 2025

Sydney, Australia, 29 July 2025: Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, is pleased to provide a summary of its activities for the quarter ended 30 June 2025.

- Key milestones in CHM CDH17 program
  - Phase 1/2 study progresses to dose level 2
  - FDA Fast Track Designation received for treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
  - Fourth US clinical site activated at the Emory Winship Cancer Institute in Atlanta
  - Translational data demonstrates CAR-T persistence
- ADVENT-AML Phase 1B Trial reports encouraging early results
- Professor Miles Prince AM Appointed to Board as Non-Executive Director
- Successful $6.6 Million Placement to Accelerate Clinical Pipeline with a total of $16.6m raised throughout the year including philanthropic donation of $4.0m

Clinical Trial Updates

CHM CDH17 Phase 1 CLINICAL PROGRAM ACCELERATES WITH DOSE ESCALATION, FDA FAST TRACK DESIGNATION, FINAL U.S. SITE ACTIVATION & TRANSLATIONAL DATA

Chimeric made significant clinical and regulatory advances in its CHM CDH17 program over the course of the reporting period, announcing four milestones:

Dose Escalation Progresses to Level 2

The ongoing Phase 1/2 study advanced to Dose Level 2 (150 million cells) after safely completing Dose Level 1. Of the four patients treated at the lower dose, three with colorectal cancer (CRC) and one with an intestinal neuroendocrine tumour (NET), no dose-limiting toxicities or off-target effects were observed. One patient experienced a manageable Grade 1 cytokine release syndrome (CRS), a common pharmacodynamic sign of CAR-T expansion. Clinical activity was observed, with the NET patient maintaining stable disease for five months, and a CRC patient continuing to exhibit stable disease at six months. These outcomes, combined with the safety

data and translational evidence of persistence, support further dose escalation and add to the body of evidence validating CHM CDH17's therapeutic potential.

Fast Track Designation

The US FDA granted Fast Track Designation to CHM CDH17 for the treatment of GEP-NETs in patients who have progressed beyond at least one prior line of therapy in the advanced or metastatic setting. Fast Track status is reserved for investigational therapies targeting serious conditions with high unmet need and provides regulatory advantages including frequent engagement with the FDA, eligibility for Rolling Biologics License Application (BLA) Review, Priority Review, and potential Accelerated Approval. This designation highlights CHM CDH17's potential as a novel treatment option for patients with limited alternatives and enhances Chimeric's ability to streamline development pathways in the US.

US Site Expansion and Recruitment

In parallel with clinical progression, Chimeric activated its fourth and final US clinical site, the Emory Winship Cancer Institute in Atlanta, Georgia an NCI-designated Comprehensive Cancer Center. The site is led by Dr Daniel Halperin, a recognised authority in the neuroendocrine tumour space and member of several key scientific advisory boards. Emory's inclusion significantly expands the geographic reach of the trial, increases recruitment capacity, and strengthens the trial's positioning within the US medical landscape.

The Phase 1/2 study (NCT06055439) is a multi-centre, open-label trial evaluating the safety, optimal dosing, persistence, and preliminary efficacy of CHM CDH17 in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours. The Phase 1 stage is expected to enrol up to 15 patients to guide dose selection, followed by indication-specific expansion cohorts in Phase 2.

Translational Data Demonstrates CAR-T Persistence

In June, Chimeric announced encouraging translational data from the trial, demonstrating that CHM CDH17 CAR-T cells expand and persist following infusion. All four subjects treated at Dose Level 1 (50 million cells) showed detectable CAR-T cell levels up to 28 days, with two subjects (who experienced prolonged stable disease) exhibiting cell persistence for up to six months. In addition, immunohistochemistry analysis confirmed cadherin-17 expression on tumour cells in all four participants, validating the target's relevance in this patient population. While derived from a small cohort, these findings provide important biological evidence of durable CAR-T cell activity and further de-risk the program as it moves through clinical development.

ENCOURAGING EARLY RESULTS FROM ADVENT-AML PHASE 1B TRIAL at MD Anderson Cancer Centre

During the period the Company reported promising early clinical activity from its ADVENT-AML Phase 1B clinical trial evaluating the combination of standard-of-care treatment with the Company's proprietary CHM CORE-NK cell therapy in frontline acute myeloid leukemia (AML).

Of the first three patients treated under the frontline ADVENT AML CHM CORE-NK protocol, two have achieved a Complete Response with incomplete blood count recovery (CRi), a meaningful remission outcome; while the third achieved Stable Disease (announced 15 May 2025). The results support the potential of CHM CORE-NK to enhance responses in elderly or unfit patients with newly diagnosed AML, who are not candidates for intensive chemotherapy or allogeneic stem cell transplant.

The ADVENT-AML trial, conducted at MD Anderson Cancer Center under Principal Investigator Dr Abhishek Maiti, is the first frontline AML study globally to incorporate a cell therapy. The study combines CORE-NK cells with azacitidine and venetoclax, aiming to establish safety and assess response durability, minimal residual disease (MRD) status, and survival metrics.

The trial remains open for enrolment in its dose expansion phase and is expected to complete in the December 2025 quarter, subject to satisfactory patient recruitment. All CHM CORE-NK cells used are cryopreserved for "off-the-shelf" use and manufactured at Case Western Reserve University, where the platform was developed.

Corporate

PROFESSOR MILES PRINCE AM APPOINTED TO BOARD AS NON-EXECUTIVE DIRECTOR

On 1 July 2025, Chimeric Therapeutics appointed Professor H. Miles Prince AM as a Non-Executive Director. Professor Prince is a highly respected and internationally recognised haematologist with a distinguished career spanning clinical medicine, cancer immunology research, and cell therapy innovation.

He holds academic appointments at both Melbourne and Monash Universities and currently serves as Professor and Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare, as well as a practising haematologist at the Peter MacCallum Cancer Centre. Professor Prince has led over 200 clinical trials, played a key role in establishing cell therapy laboratories at Peter MacCallum, and pioneered early CAR-T trials at both Epworth and Peter Mac.

He has authored over 500 peer-reviewed publications and is known for his contributions to both scientific progress and healthcare advocacy. Professor Prince is a founding member of the

Snowdome Foundation, which aims to accelerate novel blood cancer therapies in Australia, and sits on the Australian Blood Cancer Taskforce, where he helped develop the country's first national strategic plan for blood cancer.

In recognition of his services to medicine and research, Professor Prince was appointed a Member of the Order of Australia (AM) in 2014.

Financials

An Appendix 4C Quarterly Cash Flow report is attached to this announcement.

As detailed in the attached ASX Appendix 4C the Company had $5.76 million in cash and cash equivalents at 30 June 2025, increasing from $5.06 million at the end of the prior quarter.

The net cash used in Operating Activities during the quarter was $4.70 million with 88% of operating activities relates to staff costs and research and development as detailed in the Appendix 4C.

The net financing inflows for the quarter was $5.70 million which consists of $3.20 million received as part of the May Placement and Entitlement Offer and $2.50 million from entering into an advance on the Company's anticipated FY25 Research and Development Tax Incentive (RDTI).

In accordance with Listing Rule 4.7C, payments made to related parties and their associated included in items 6.1 of the Appendix 4C include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses. The Board has focused on prudent management of cash and as a result careful cost cutting strategy projected total expenditure has and will continue to be reduced.

SUCCESSFUL $6.6 MILLION PLACEMENT TO ACCELERATE CLINICAL PIPELINE

In May, the Company secured firm commitments to raise $6.6 million (before costs) through a two-tranche placement to institutional, sophisticated, and professional investors. The placement was strongly supported, with allocations scaled back due to excess demand, and included cornerstone participation from a US-based family office.

The placement comprises approximately 1.65 billion new shares issued at $0.004 per share, alongside 1.65 billion unlisted options exercisable at $0.004. Investors who exercise these options within five months will be eligible for an additional 1.65 billion contingent options exercisable at $0.005. Tranche 1 (~$657,000) will be issued under existing capacity, while Tranche 2 (~$5.94 million) was given shareholder approval at an EGM held on 23 July 2025.

Proceeds will primarily be used to:

- Progress the CHM CDH17 CAR-T clinical trial, which is advancing to dose level 2 with encouraging early data and strong recruitment
- Support ongoing Phase 1B trials of the CORE-NK platform in acute myeloid leukemia (AML)
- Fund general working capital and capital raising expenses

In conjunction with the placement, Chimeric exercised its right to terminate the existing Placement Agreement with Lind Global Fund II, LP, as announced on 23 June 2023.

$2.5 MILLION NON-DILUTIVE FUNDING SECURED VIA R&D TAX INCENTIVE FACILITY

In June 2025, Chimeric Therapeutics secured $2.5 million in non-dilutive funding through a financing facility with Endpoints Capital, backed by the Company's anticipated FY25 Research and Development Tax Incentive (RDTI). The funding provides Chimeric with early access to a portion of its expected RDTI rebate and further strengthens its balance sheet following the $6.6 million placement, $1 million entitlement offer and $4 million in additional non-dilutive capital raised in recent months.

The facility is secured against Chimeric's anticipated RDTI refund from the Australian Taxation Office and is subject to a commercial interest rate. Repayment is expected upon receipt of the rebate by 31 December 2025, although the facility can be repaid earlier without penalty, subject to a minimum interest period of 60 days.

ENTITLEMENT OFFER COMPLETED

In April, Chimeric completed a non-renounceable entitlement offer, raising approximately $1 million through valid applications for 197.2 million new shares from 365 shareholders. Participants received 2 new shares and 1 attaching option (exercise price $0.008) for every 5 shares held, at an issue price of $0.005 per share.

LIND FACILITY AGREEMENT CONCLUDED

Further to the announcement made on 20 May 2025, the Company has since fulfilled its obligations under the Placement Agreement with Lind and has settled all outstanding obligations following the issue of equity.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company is focused on bringing the promise of cell therapy to life for more patients with cancer.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, Professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated.

CHM CLTX is a novel CAR-T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is in a phase 1B clinical trial in recurrent/progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper.

Contact

Investors
Dr Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Chimeric Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
68 638 835 828	30 June 2025

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers (inclusive of GST)	-	3,969
1.2	Payments for (inclusive of GST)		
	(a) research and development	(3,463)	(8,941)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs*	(694)	(4,462)
	(f) administration and corporate costs	(584)	(2,255)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	6	48
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	4,172
1.8	Other (provide details if material)	31	186
1.9	**Net cash from / (used in) operating activities**	**(4,704)**	**(7,283)**

*Staff costs includes staff, directors, scientific advisors and employment related costs.

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	3,204	8,204
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(184)	(572)
3.5	Proceeds from borrowings	2,500	4,062
3.6	Repayment of borrowings	-	(1,562)
3.7	Transaction costs related to loans and borrowings	-	(86)
3.8	Dividends paid	-	-
3.9	Other – payments of licence fee liabilities	-	-
3.10	**Net cash from / (used in) financing activities**	**5,520**	**10,046**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	5,059	3,053
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,704)	(7,283)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	5,520	10,046
4.5	Effect of movement in exchange rates on cash held	(118)	(59)
4.6	**Cash and cash equivalents at end of period**	**5,757**	**5,757**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	5,757	5,059
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**5,757**	5,059

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	75
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1 – Include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(4,704)
8.2	Cash and cash equivalents at quarter end (item 4.6)	5,757
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	5,757
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	1.22

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

- The Company does expect to continue to have a similar level of net operating cash flows.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

- On 20 May 2025, the Company announced that they had raised $6.6 million as part of a Placement with $4.4 million to be received after the EGM on 23 July 2025.
- In addition to the shares, investors will receive a free-attaching options that can be exercised at $0.004 and expires 8 months from issuance. Each option exercised withing 5 months of issue will trigger an additional option exercisable at $0.005 expiring 8 months from issuance.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

- Yes, the Board expects to be able to continue its operations and to meet its business objectives based on the responses detailed in 8.6.1 and 8.6.2.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 29 July 2025

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

+61 3 9824 5254
info@chimerictherapeutics.com

Chimeric Therapeutics Limited
ACN 638 835 828

ASX: CHM